Abhishek A. Chakraborty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abhishek A. Chakraborty has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Treg Grubb
Department of Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, USA
25 shared publications- Kristopher A. Sarosiek
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
20 shared publications Laura Stransky
20 shared publicationsSmruthi Maganti
20 shared publications- Cameron Fraser
John B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health, Boston, USA
19 shared publications - Francisca Vazquez
Broad Institute of MIT and Harvard, Cambridge, USA
19 shared publications
Latest Publications
- 21 September 2026
- Published by Kidney Cancer Association (KCA) in Kidney Cancer Journal
- Vol. 24 (3) , 110-123
Multi-omics Approaches Identify Uremic Toxins and Immune Regulators as Circulating Biomarkers of Metastatic RCC
BACKGROUND: The diagnosis and treatment of metastatic renal cell carcinoma (mRCC) is challenging. Drug combinations targeting the immune checkpoint and angiogenesis have improved clinical outcomes. However, non-invasive diagnostic and prognostic biomarkers of mRCC are lacking. RESULTS: Using plasma samples from 56 RCC patients (n=22 localized versus n=34 metastatic disease), we leveraged two recent methods: (1) high-throughput proteomics and (2) gut microbiome-focused targeted metabolomics, for non-invasive biomarker identification of localized vs mRCC (Two-sample t-tests: FDR<20% and p<0.027). Elevated biomarkers in mRCC included soluble PD-L1 (sPD-L1, p<0.0001) and CLMP (p=0.002), as determined by proteomics; and indole (p<0.0001), 5-hydroxy-indole acetic acid (5-HIAA, p=0.002), and phenylacetylglutamine (PAGln, p=0.005), as determined by microbial metabolomics. CONCLUSIONS: sPD-L1, indole derivatives, and PAGln, which have links to immune regulation and nephric integrity, were identified as biomarkers of mRCC. Follow-up studies with larger cohorts will address the oncogenic mechanisms and relevance of these biomarkers in therapy response.
- 21 September 2026
- Published by Kidney Cancer Association (KCA) in Kidney Cancer Journal
- Vol. 24 (3) , 110-123
Multi-omics Approaches Identify Uremic Toxins and Immune Regulators as Circulating Biomarkers of Metastatic RCC
BACKGROUND: The diagnosis and treatment of metastatic renal cell carcinoma (mRCC) is challenging. Drug combinations targeting the immune checkpoint and angiogenesis have improved clinical outcomes. However, non-invasive diagnostic and prognostic biomarkers of mRCC are lacking. RESULTS: Using plasma samples from 56 RCC patients (n=22 localized versus n=34 metastatic disease), we leveraged two recent methods: (1) high-throughput proteomics and (2) gut microbiome-focused targeted metabolomics, for non-invasive biomarker identification of localized vs mRCC (Two-sample t-tests: FDR<20% and p<0.027). Elevated biomarkers in mRCC included soluble PD-L1 (sPD-L1, p<0.0001) and CLMP (p=0.002), as determined by proteomics; and indole (p<0.0001), 5-hydroxy-indole acetic acid (5-HIAA, p=0.002), and phenylacetylglutamine (PAGln, p=0.005), as determined by microbial metabolomics. CONCLUSIONS: sPD-L1, indole derivatives, and PAGln, which have links to immune regulation and nephric integrity, were identified as biomarkers of mRCC. Follow-up studies with larger cohorts will address the oncogenic mechanisms and relevance of these biomarkers in therapy response.
- Open Access
- 11 September 2026
- Published by Springer Nature in Cell Death & Disease
BCL-XL dependence is a subtype agnostic actionable feature of difficult-to-treat kidney cancers
BCL-X L is a BCL-2 family anti-apoptotic protein that functions as a targetable dependency in clear cell Renal Cell Carcinoma (ccRCC), the most common form of adult kidney cancer. However, the mechanisms driving this dependence are unclear. Moreover, although significant strides have been made in managing ccRCC, advanced/metastatic cases of this disease and other rarer RCC subtypes [e.g., Fumarate Hydratase (FH)-deficient and sarcomatoid tumors] lack durable therapies and have poor clinical outcomes. Here, we interrogated the mechanisms and extent of BCL-X L dependence to address its potential therapeutic utility in clinically challenging cases of kidney cancer. In a panel of physiologically relevant cell lines representing several RCC subtypes, we used pharmacological or genetic tools to perturb cell state and FH biology and measured the impact of these perturbations on response to pharmacological BCL-X L inhibition. Simultaneously, in vivo studies addressed the importance of BCL-X L blockade in metastatic RCC. Finally, using a machine-learning model trained on the human RCC TCGA dataset called ‘Transcriptional Prediction of Lethality (TrPLet)’, we computationally predicted and then validated BCL-X L dependence in all RCC subtypes. This analysis identified the cellular determinants of BCL-X L dependence, including high expression of BCL-X L , CD44, and NOXA. We found that disparate biological programs, such as cell state changes, an ‘anoikis’-like program, inflammatory state, and metabolic perturbations (e.g., fumarate production in FH-deficient RCCs) – which converge directly or indirectly on AMPK activation – conferred increased BCL-X L dependence in various RCC subtypes. Remarkably, correlation studies using the DepMap dataset revealed that increased AMPK isoform 2 ( PRKAA2 ) expression was a kidney lineage-specific biomarker of BCL-X L dependence. Indeed, pharmacological AMPK activation sensitized RCCs to BCL-X L blockade. Altogether, our work offers mechanistic insights on BCL-X L dependence and establishes a biomarker panel for patient stratification to ultimately credential BCL-X L as a subtype agnostic vulnerability in difficult-to-treat RCCs.
- 11 September 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessBCL-XL dependence is a subtype agnostic actionable feature of difficult-to-treat kidney cancers
BCL-X L is a BCL-2 family anti-apoptotic protein that functions as a targetable dependency in clear cell Renal Cell Carcinoma (ccRCC), the most common form of adult kidney cancer. However, the mechanisms driving this dependence are unclear. Moreover, although significant strides have been made in managing ccRCC, advanced/metastatic cases of this disease and other rarer RCC subtypes [e.g., Fumarate Hydratase (FH)-deficient and sarcomatoid tumors] lack durable therapies and have poor clinical outcomes. Here, we interrogated the mechanisms and extent of BCL-X L dependence to address its potential therapeutic utility in clinically challenging cases of kidney cancer. In a panel of physiologically relevant cell lines representing several RCC subtypes, we used pharmacological or genetic tools to perturb cell state and FH biology and measured the impact of these perturbations on response to pharmacological BCL-X L inhibition. Simultaneously, in vivo studies addressed the importance of BCL-X L blockade in metastatic RCC. Finally, using a machine-learning model trained on the human RCC TCGA dataset called ‘Transcriptional Prediction of Lethality (TrPLet)’, we computationally predicted and then validated BCL-X L dependence in all RCC subtypes. This analysis identified the cellular determinants of BCL-X L dependence, including high expression of BCL-X L , CD44, and NOXA. We found that disparate biological programs, such as cell state changes, an ‘anoikis’-like program, inflammatory state, and metabolic perturbations (e.g., fumarate production in FH-deficient RCCs) – which converge directly or indirectly on AMPK activation – conferred increased BCL-X L dependence in various RCC subtypes. Remarkably, correlation studies using the DepMap dataset revealed that increased AMPK isoform 2 ( PRKAA2 ) expression was a kidney lineage-specific biomarker of BCL-X L dependence. Indeed, pharmacological AMPK activation sensitized RCCs to BCL-X L blockade. Altogether, our work offers mechanistic insights on BCL-X L dependence and establishes a biomarker panel for patient stratification to ultimately credential BCL-X L as a subtype agnostic vulnerability in difficult-to-treat RCCs.
- Open Access
- 10 September 2026
- Published by Wiley in The Journal of Physiology
- Vol. 604 (18) , 7539-7558
Hypoxia‐inducible factor‐1a (HIF1a) as a context‐dependent integrator of metabolic stress in skeletal muscle
Skeletal muscle experiences large fluctuations in ATP demand and redox state during contraction, ischaemia and chronic disease, requiring rapid adaptations in substrate selection, mitochondrial workload, vascular coupling, regeneration and protein homeostasis. Hypoxia‐inducible factor‐1a (HIF1a) is classically viewed as an oxygen‐responsive transcription factor that mediates rapid adaptation to hypoxia. Accumulating evidence across tissues, including skeletal muscle, indicates that HIF1a is also responsive to physiological and pathological inputs, such as exercise, circadian timing, redox perturbations and endogenous/exogenous cytotoxins, even when tissue hypoxia is not detectable. During hypoxia, including transient mismatches between oxygen demand and supply during muscle contraction, HIF1a activation shifts metabolism from oxidative to non‐oxidative energy production, suppresses non‐essential energy‐consuming processes, including protein homeostasis, and promotes vascular responses that improve oxygen delivery. Under normoxic conditions, persistent HIF1a activation promotes maladaptive responses, including impaired mitochondrial remodelling, reduced anabolic responsiveness, defective regeneration, fibrosis, and atrophy‐ and senescence‐associated reprogramming. Current evidence shows that this shift from adaptive to maladaptive signalling is determined in part by post‐translational mechanisms that regulate signalling duration and target gene engagement, as well as by fibre type, circadian state and the nature of the upstream stressor. Unlike the robust responses in muscle tissue observed in preclinical models, human muscle biopsies often show modest or transient HIF1a accumulation, yet transcriptional responses indicate meaningful pathway activation, suggesting that biologically relevant signalling occurs even when total protein levels appear low. Genetic models, multiomics, and human studies support HIF1a as a context‐dependent regulator of metabolic reprogramming that balances short‐term adaptation with long‐term energetic cost. image
- 10 September 2026
- Published by Wiley in The Journal of Physiology
- Vol. 604 (18) , 7539-7558
Open AccessHypoxia‐inducible factor‐1a (HIF1a) as a context‐dependent integrator of metabolic stress in skeletal muscle
Skeletal muscle experiences large fluctuations in ATP demand and redox state during contraction, ischaemia and chronic disease, requiring rapid adaptations in substrate selection, mitochondrial workload, vascular coupling, regeneration and protein homeostasis. Hypoxia‐inducible factor‐1a (HIF1a) is classically viewed as an oxygen‐responsive transcription factor that mediates rapid adaptation to hypoxia. Accumulating evidence across tissues, including skeletal muscle, indicates that HIF1a is also responsive to physiological and pathological inputs, such as exercise, circadian timing, redox perturbations and endogenous/exogenous cytotoxins, even when tissue hypoxia is not detectable. During hypoxia, including transient mismatches between oxygen demand and supply during muscle contraction, HIF1a activation shifts metabolism from oxidative to non‐oxidative energy production, suppresses non‐essential energy‐consuming processes, including protein homeostasis, and promotes vascular responses that improve oxygen delivery. Under normoxic conditions, persistent HIF1a activation promotes maladaptive responses, including impaired mitochondrial remodelling, reduced anabolic responsiveness, defective regeneration, fibrosis, and atrophy‐ and senescence‐associated reprogramming. Current evidence shows that this shift from adaptive to maladaptive signalling is determined in part by post‐translational mechanisms that regulate signalling duration and target gene engagement, as well as by fibre type, circadian state and the nature of the upstream stressor. Unlike the robust responses in muscle tissue observed in preclinical models, human muscle biopsies often show modest or transient HIF1a accumulation, yet transcriptional responses indicate meaningful pathway activation, suggesting that biologically relevant signalling occurs even when total protein levels appear low. Genetic models, multiomics, and human studies support HIF1a as a context‐dependent regulator of metabolic reprogramming that balances short‐term adaptation with long‐term energetic cost. image
- Open Access
- 22 April 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (11) , 3763-3787
Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolism
Renal cell carcinomas (RCCs) depend on the trimeric sodium-coupled aspartate and glutamate transporter, SLC1A1/EAAT3; however, pharmacologically targeting SLC1A1 is challenging. Here we determined a cryo-EM structure of human SLC1A1 bound to compound 3e, a recently described SLC1A1-selective bicyclic imidazo[1,2 α]pyridine-3-amine (BIA) inhibitor with an unclear mechanism of action. 3e binds a membrane-embedded allosteric pocket accessible only in the apo state, when SLC1A1 is unbound to substrate and sodium, and likely prevents sodium and substrate binding. Moreover, by forming a wedge between the trimerization domain and the substrate-binding transport domain, alongside a cholesterol moiety from the lipid bilayer, 3e blocks SLC1A1’s elevator-like movements that support the transport cycle. Mutations in this binding pocket abolish the 3e interaction and counteract 3e’s cytotoxicity in RCC cells, confirming on-target activity and explaining SLC1A1 selectivity. The subsequent design of two new SLC1A1-selective BIA derivatives, PBJ1 and PBJ2, was directed by the SLC1A1-3e structures; both inhibited SLC1A1-dependent aspartate, glutamate, and cysteine metabolism and showed enhanced cytotoxicity.
- 22 April 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (11) , 3763-3787
Open AccessStructure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolism
Renal cell carcinomas (RCCs) depend on the trimeric sodium-coupled aspartate and glutamate transporter, SLC1A1/EAAT3; however, pharmacologically targeting SLC1A1 is challenging. Here we determined a cryo-EM structure of human SLC1A1 bound to compound 3e, a recently described SLC1A1-selective bicyclic imidazo[1,2 α]pyridine-3-amine (BIA) inhibitor with an unclear mechanism of action. 3e binds a membrane-embedded allosteric pocket accessible only in the apo state, when SLC1A1 is unbound to substrate and sodium, and likely prevents sodium and substrate binding. Moreover, by forming a wedge between the trimerization domain and the substrate-binding transport domain, alongside a cholesterol moiety from the lipid bilayer, 3e blocks SLC1A1’s elevator-like movements that support the transport cycle. Mutations in this binding pocket abolish the 3e interaction and counteract 3e’s cytotoxicity in RCC cells, confirming on-target activity and explaining SLC1A1 selectivity. The subsequent design of two new SLC1A1-selective BIA derivatives, PBJ1 and PBJ2, was directed by the SLC1A1-3e structures; both inhibited SLC1A1-dependent aspartate, glutamate, and cysteine metabolism and showed enhanced cytotoxicity.
- Open Access
BCL-XL Dependence is a Subtype Agnostic Actionable Feature of Difficult-to-Treat Kidney Cancers
The BCL-XL anti-apoptotic protein is a clear cell Renal Cell Carcinoma (ccRCC) dependency; however, the mechanism of this dependence and its relevance in other aggressive kidney cancer contexts, including metastatic and/or rare RCC subtypes [e.g., Fumarate Hydratase (FH)-deficient and sarcomatoid RCCs], is unknown. Computational predictions, using a machine learning model trained on the human RCC TCGA dataset, and cell-based validations, confirmed BCL-XL dependence in all RCC subtypes. Remarkably, cell state changes, anoikis programs, inflammatory state, and metabolic perturbations (e.g., fumarate production in FH-deficient RCCs) independently conferred increased BCL-XL dependence. Correlation studies revealed that increased AMPK isoform 2 (PRKAA2) expression is a kidney-specific biomarker of BCL-XL dependence. Indeed, pharmacological AMPK activation sensitized RCCs to BCL-XL blockade. Finally, using functional studies, we developed a multivariate model that accurately predicted BCL-XL dependence in RCC. Our studies offer biomarkers for patient stratification and credential BCL-XL as a subtype agnostic vulnerability in difficult-to-treat RCCs.
Open AccessBCL-XL Dependence is a Subtype Agnostic Actionable Feature of Difficult-to-Treat Kidney Cancers
The BCL-XL anti-apoptotic protein is a clear cell Renal Cell Carcinoma (ccRCC) dependency; however, the mechanism of this dependence and its relevance in other aggressive kidney cancer contexts, including metastatic and/or rare RCC subtypes [e.g., Fumarate Hydratase (FH)-deficient and sarcomatoid RCCs], is unknown. Computational predictions, using a machine learning model trained on the human RCC TCGA dataset, and cell-based validations, confirmed BCL-XL dependence in all RCC subtypes. Remarkably, cell state changes, anoikis programs, inflammatory state, and metabolic perturbations (e.g., fumarate production in FH-deficient RCCs) independently conferred increased BCL-XL dependence. Correlation studies revealed that increased AMPK isoform 2 (PRKAA2) expression is a kidney-specific biomarker of BCL-XL dependence. Indeed, pharmacological AMPK activation sensitized RCCs to BCL-XL blockade. Finally, using functional studies, we developed a multivariate model that accurately predicted BCL-XL dependence in RCC. Our studies offer biomarkers for patient stratification and credential BCL-XL as a subtype agnostic vulnerability in difficult-to-treat RCCs.
- Open Access
- 14 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10012
The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs
Epigenetic dysregulation, including accumulation of Histone H3 lysine 27 acetylation (H3K27ac), is a hallmark of pVHL-deficient clear cell Renal Cell Carcinomas (ccRCCs). Using an in vivo positive selection ORF screen in poorly tumorigenic pVHL-proficient cells and mechanistic studies in pVHL-deficient cells, we discovered that the aspartate (Asp) and glutamate (Glu) transporter, SLC1A1/EAAT3, is a metabolic dependency in ccRCC. pVHL loss promotes Hypoxia Inducible Factor (HIF)-independent SLC1A1 expression via H3K27ac dysregulation. SLC1A1 inactivation, genetically or pharmacologically, depletes Asp/Glu-derived metabolites (e.g., Tricarboxylic acid cycle and nucleotide intermediates), impedes ccRCC growth, and sensitizes ccRCCs to anti-metabolite drugs (e.g., glutaminase blockers). In human tumors, higher SLC1A1 expression is associated with reduced immune infiltration, oncogenic metabolic programs, and advanced stage/metastatic disease. Finally, in ccRCC animal models, SLC1A1 inactivation diminishes lung metastasis and the outgrowth of established renal tumors. Altogether, our studies credential SLC1A1 as an actionable, HIF-independent, metabolic dependency in pVHL-deficient ccRCCs.
- 14 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10012
Open AccessThe SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs
Epigenetic dysregulation, including accumulation of Histone H3 lysine 27 acetylation (H3K27ac), is a hallmark of pVHL-deficient clear cell Renal Cell Carcinomas (ccRCCs). Using an in vivo positive selection ORF screen in poorly tumorigenic pVHL-proficient cells and mechanistic studies in pVHL-deficient cells, we discovered that the aspartate (Asp) and glutamate (Glu) transporter, SLC1A1/EAAT3, is a metabolic dependency in ccRCC. pVHL loss promotes Hypoxia Inducible Factor (HIF)-independent SLC1A1 expression via H3K27ac dysregulation. SLC1A1 inactivation, genetically or pharmacologically, depletes Asp/Glu-derived metabolites (e.g., Tricarboxylic acid cycle and nucleotide intermediates), impedes ccRCC growth, and sensitizes ccRCCs to anti-metabolite drugs (e.g., glutaminase blockers). In human tumors, higher SLC1A1 expression is associated with reduced immune infiltration, oncogenic metabolic programs, and advanced stage/metastatic disease. Finally, in ccRCC animal models, SLC1A1 inactivation diminishes lung metastasis and the outgrowth of established renal tumors. Altogether, our studies credential SLC1A1 as an actionable, HIF-independent, metabolic dependency in pVHL-deficient ccRCCs.
- 5 April 2024
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 22 (2.5)
YIA24-006: The NF-I/a Transcription Factor is a HIF-Independent Oncogenic Dependency in Kidney Cancer
"YIA24-006: The NF-I/a Transcription Factor is a HIF-Independent Oncogenic Dependency in Kidney Cancer" published on 05 Apr 2024 by National Comprehensive Cancer Network.
- 5 April 2024
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 22 (2.5)
YIA24-006: The NF-I/a Transcription Factor is a HIF-Independent Oncogenic Dependency in Kidney Cancer
"YIA24-006: The NF-I/a Transcription Factor is a HIF-Independent Oncogenic Dependency in Kidney Cancer" published on 05 Apr 2024 by National Comprehensive Cancer Network.
- Open Access
- 15 November 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (22)
Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer
Half of all men with advanced prostate cancer (PCa) inherit at least 1 copy of an adrenal-permissive HSD3B1 (1245C) allele, which increases levels of 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) and promotes intracellular androgen biosynthesis. Germline inheritance of the adrenally permissive allele confers worse outcomes in men with advanced PCa. We investigated whether HSD3B1 (1245C) drives resistance to combined androgen deprivation and radiotherapy. Adrenally permissive 3βHSD1 enhanced resistance to radiotherapy in PCa cell lines and xenograft models engineered to mimic the human adrenal/gonadal axis during androgen deprivation. The allele-specific effects on radiosensitivity were dependent on availability of DHEA, the substrate for 3βHSD1. In lines expressing the HSD3B1 (1245C) allele, enhanced expression of DNA damage response (DDR) genes and more rapid DNA double-strand break (DSB) resolution were observed. A correlation between androgen receptor (AR) expression and increased DDR gene expression was confirmed in 680 radical prostatectomy specimens. Treatment with the nonsteroidal antiandrogen enzalutamide reversed the resistant phenotype of HSD3B1 (1245C) PCa in vitro and in vivo. In conclusion, 3βHSD1 promotes prostate cancer resistance to combined androgen deprivation and radiotherapy by upregulating DNA DSB repair. This work supports prospective validation of early combined androgen blockade for high-risk men harboring the HSD3B1 (1245C) allele.
- 15 November 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (22)
Open AccessIntratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer
Half of all men with advanced prostate cancer (PCa) inherit at least 1 copy of an adrenal-permissive HSD3B1 (1245C) allele, which increases levels of 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) and promotes intracellular androgen biosynthesis. Germline inheritance of the adrenally permissive allele confers worse outcomes in men with advanced PCa. We investigated whether HSD3B1 (1245C) drives resistance to combined androgen deprivation and radiotherapy. Adrenally permissive 3βHSD1 enhanced resistance to radiotherapy in PCa cell lines and xenograft models engineered to mimic the human adrenal/gonadal axis during androgen deprivation. The allele-specific effects on radiosensitivity were dependent on availability of DHEA, the substrate for 3βHSD1. In lines expressing the HSD3B1 (1245C) allele, enhanced expression of DNA damage response (DDR) genes and more rapid DNA double-strand break (DSB) resolution were observed. A correlation between androgen receptor (AR) expression and increased DDR gene expression was confirmed in 680 radical prostatectomy specimens. Treatment with the nonsteroidal antiandrogen enzalutamide reversed the resistant phenotype of HSD3B1 (1245C) PCa in vitro and in vivo. In conclusion, 3βHSD1 promotes prostate cancer resistance to combined androgen deprivation and radiotherapy by upregulating DNA DSB repair. This work supports prospective validation of early combined androgen blockade for high-risk men harboring the HSD3B1 (1245C) allele.
- 13 September 2023
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 37 (5)
Contributors
- 13 September 2023
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 37 (5)
Contributors
- 13 September 2023
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 37 (5)
Copyright
- 13 September 2023
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 37 (5)
Copyright